Oral candidiasis: effects of antifungal therapy upon clinical signs and symptoms, salivary antibody, and mucosal adherence of Candida albicans.
A human study of the effects of topical nystatin (Mycostatin) therapy of oral candidiasis showed that effects of treatment were limited to the time in which the drug was used. Two weeks of therapy resulted in significant reduction in number of organisms and marked improvement in signs and symptoms of candidiasis. The condition recurred rapidly following cessation of treatment. No change in specific anticandida antibody in saliva or in adherence of Candida albicans to mucosal epithelium (in vitro) was seen with treatment.
D000908:Antibodies, Fungal / Q000032:analysis; D002176:Candida albicans / Q000187:drug effects / Q000276:immunology; D002180:Candidiasis, Oral / Q000188:drug therapy*; D006801:Humans; D009061:Mouth Mucosa / Q000382:microbiology; D009761:Nystatin / Q000494:pharmacology*; D012008:Recurrence; D012463:Saliva / Q000276:immunology
D000908:Antibodies, Fungal; D009761:Nystatin